

# Zachary A Cooper

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7688177/publications.pdf>

Version: 2024-02-01

77  
papers

18,231  
citations

50276

46  
h-index

85541

71  
g-index

80  
all docs

80  
docs citations

80  
times ranked

26035  
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC. JCI Insight, 2022, 7, .	5.0	42
2	COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2022, 40, 3383-3393.	1.6	120
3	Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature, 2022, 606, 797-803.	27.8	54
4	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nature Medicine, 2021, 27, 1432-1441.	30.7	216
5	The Combiome Hypothesis: Selecting Optimal Treatment for Cancer Patients. Clinical Lung Cancer, 2021, , .	2.6	4
6	Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in BRAF-mutated melanoma. Oncoimmunology, 2021, 10, 1992880.	4.6	7
7	Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. , 2020, 8, e001095.		27
8	Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. Cancer Immunology Research, 2020, 8, 1365-1380.	3.4	37
9	Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade. , 2020, 8, e000610.		70
10	The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science, 2020, 368, 973-980.	12.6	1,077
11	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nature Communications, 2020, 11, 1839.	12.8	15
12	Immunosuppressive adenosine - a novel treatment target for multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e137-e138.	0.4	0
13	A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. Oncoimmunology, 2018, 7, e1423172.	4.6	25
14	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncology, The, 2018, 19, 181-193.	10.7	233
15	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science, 2018, 359, 97-103.	12.6	3,126
16	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell, 2018, 175, 998-1013.e20.	28.9	1,260
17	Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma. Cancer Discovery, 2018, 8, 1366-1375.	9.4	80
18	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Science Translational Medicine, 2017, 9, .	12.4	689

#	ARTICLE	IF	CITATIONS
19	An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. <i>Journal of Experimental Medicine</i> , 2017, 214, 1691-1710.	8.5	71
20	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017, 2, .	3.8	120
21	Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. <i>Science</i> , 2017, 357, 1156-1160.	12.6	1,059
22	Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. <i>EMBO Molecular Medicine</i> , 2017, 9, 1011-1029.	6.9	63
23	Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. <i>Oncolmunology</i> , 2017, 6, e1361097.	4.6	50
24	Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. <i>Oncolmunology</i> , 2017, 6, e1321187.	4.6	45
25	Targeted Therapies Combined With Immune Checkpoint Therapy. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 138-146.	2.0	36
26	sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. <i>Nature</i> , 2016, 532, 250-254.	27.8	290
27	Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Resistant Refractory Metastatic Melanoma. <i>JAMA Oncology</i> , 2016, 2, 1056.	7.1	41
28	Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 5553-5563.	7.0	96
29	Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2442-2454.	4.1	47
30	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2016, 6, 827-837.	9.4	785
31	Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 202-216.	9.4	1,158
32	Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. <i>Cancer Cell</i> , 2016, 29, 270-284.	16.8	198
33	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. <i>Oncolmunology</i> , 2016, 5, e1136044.	4.6	55
34	Novel Treatments in Development for Melanoma. <i>Cancer Treatment and Research</i> , 2016, 167, 371-416.	0.5	15
35	Working with Human Tissues for Translational Cancer Research. <i>Journal of Visualized Experiments</i> , 2015, , .	0.3	2
36	Update on use of aldesleukin for treatment of high-risk metastatic melanoma. <i>ImmunoTargets and Therapy</i> , 2015, 4, 79.	5.8	21

#	ARTICLE	IF	CITATIONS
37	Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 3102-3104.	7.0	27
38	Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. <i>Cell Reports</i> , 2015, 11, 1458-1473.	6.4	55
39	The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. <i>Nature Genetics</i> , 2015, 47, 250-256.	21.4	434
40	Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. <i>Seminars in Oncology</i> , 2015, 42, 601-616.	2.2	139
41	Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. <i>Journal of Clinical Investigation</i> , 2015, 125, 1459-1470.	8.2	106
42	Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. <i>PLoS ONE</i> , 2015, 10, e0140310.	2.5	39
43	Combination BRAF-Directed Therapy and Immunotherapy. <i>Cancer Drug Discovery and Development</i> , 2015, , 163-182.	0.4	0
44	Raising the bar: optimizing combinations of targeted therapy and immunotherapy. <i>Annals of Translational Medicine</i> , 2015, 3, 272.	1.7	0
45	RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma. <i>Journal of Pigmentary Disorders</i> , 2014, 01, .	0.2	0
46	Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation. <i>Journal of Immunology</i> , 2014, 193, 4722-4731.	0.8	136
47	Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma. <i>Oncotarget</i> , 2014, 3, e954956.	4.6	19
48	Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer. <i>Cancer Discovery</i> , 2014, 4, 1377-1386.	9.4	76
49	Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1 $\beta$ and Oxidative Phosphorylation in Melanoma. <i>Cancer Research</i> , 2014, 74, 7037-7047.	0.9	161
50	The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNF $\alpha$ . <i>Cancer Discovery</i> , 2014, 4, 1214-1229.	9.4	174
51	Systematic identification of signaling pathways with potential to confer anticancer drug resistance. <i>Science Signaling</i> , 2014, 7, ra121.	3.6	163
52	Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade. <i>Cancer Immunology Research</i> , 2014, 2, 643-654.	3.4	226
53	Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics. <i>PLoS ONE</i> , 2014, 9, e101286.	2.5	42
54	MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition. <i>Cancer Discovery</i> , 2014, 4, 61-68.	9.4	419

#	ARTICLE	IF	CITATIONS
55	A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors. <i>Cancer Discovery</i> , 2014, 4, 816-827.	9.4	448
56	PDGFR $\alpha$ up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. <i>Oncotarget</i> , 2014, 5, 1926-1941.	1.8	57
57	Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. <i>Cancer Biology and Medicine</i> , 2014, 11, 237-46.	3.0	64
58	Abstract 3703: PDGFR $\alpha$ up-regulation mediated by Sonic Hedgehog Pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. , 2014, , .		0
59	Toll-like Receptor Agonists and Febrile Range Hyperthermia Synergize to Induce Heat Shock Protein 70 Expression and Extracellular Release. <i>Journal of Biological Chemistry</i> , 2013, 288, 2756-2766.	3.4	59
60	BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2013, 19, 1225-1231.	7.0	832
61	BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice. <i>Clinical Cancer Research</i> , 2013, 19, 393-403.	7.0	336
62	BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. <i>Onc Immunology</i> , 2013, 2, e26615.	4.6	97
63	Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2. <i>Cancer Discovery</i> , 2013, 3, 1378-1393.	9.4	197
64	Elucidating Distinct Roles for $\kappa$ -NF1 in Melanomagenesis. <i>Cancer Discovery</i> , 2013, 3, 338-349.	9.4	213
65	Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma. <i>Onc Immunology</i> , 2013, 2, e24320.	4.6	40
66	Whole exome and whole transcriptome sequencing in melanoma patients to identify mechanisms of resistance to combined RAF/MEK inhibition.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9015-9015.	1.6	3
67	Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 5329-5340.	7.0	266
68	Targeting the MAGE A3 antigen in pancreatic cancer. <i>Surgery</i> , 2012, 152, S13-S18.	1.9	18
69	Histone Deacetylase 6 (HDAC6) Deacetylates Survivin for Its Nuclear Export in Breast Cancer. <i>Journal of Biological Chemistry</i> , 2012, 287, 10885-10893.	3.4	65
70	Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. <i>Nature</i> , 2012, 487, 500-504.	27.8	1,561
71	Rapamycin induces the anti-apoptotic protein survivin in neuroblastoma. <i>International Journal of Biochemistry and Molecular Biology</i> , 2012, 3, 28-35.	0.1	7
72	Febrile range temperature represses TNF $\alpha$ gene expression in LPS-stimulated macrophages by selectively blocking recruitment of Sp1 to the TNF $\alpha$ promoter. <i>Cell Stress and Chaperones</i> , 2010, 15, 665-673.	2.9	19

#	ARTICLE	IF	CITATIONS
73	EGF regulates survivin stability through the Raf-1/ERK pathway in insulin-secreting pancreatic $\beta$ -cells. BMC Molecular Biology, 2010, 11, 66.	3.0	33
74	Acetylation Directs Survivin Nuclear Localization to Repress STAT3 Oncogenic Activity. Journal of Biological Chemistry, 2010, 285, 36129-36137.	3.4	80
75	Febrile-range temperature modifies cytokine gene expression in LPS-stimulated macrophages by differentially modifying NF- $\kappa$ B recruitment to cytokine gene promoters. American Journal of Physiology - Cell Physiology, 2010, 298, C171-C181.	4.6	47
76	Macrophages Produce TGF- $\beta$ -Induced ( $\beta$ -ig-h3) following Ingestion of Apoptotic Cells and Regulate MMP14 Levels and Collagen Turnover in Fibroblasts. Journal of Immunology, 2008, 180, 5036-5044.	0.8	92
77	Heat Shock Co-Activates Interleukin-8 Transcription. American Journal of Respiratory Cell and Molecular Biology, 2008, 39, 235-242.	2.9	55